133 related articles for article (PubMed ID: 34405338)
1. Tailoring drug co-delivery nanosystem for mitigating U-87 stem cells drug resistance.
Behrooz AB; Vazifehmand R; Tajudin AA; Masarudin MJ; Sekawi Z; Masomian M; Syahir A
Drug Deliv Transl Res; 2022 May; 12(5):1253-1269. PubMed ID: 34405338
[TBL] [Abstract][Full Text] [Related]
2. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutics and drug-delivery approaches in the modulation of glioblastoma stem cell resistance.
Smiley SB; Zarrinmayeh H; Das SK; Pollok KE; Vannier MW; Veronesi MC
Ther Deliv; 2022 Apr; 13(4):249-273. PubMed ID: 35615860
[TBL] [Abstract][Full Text] [Related]
4. Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.
Smiley SB; Yun Y; Ayyagari P; Shannon HE; Pollok KE; Vannier MW; Das SK; Veronesi MC
Pharm Res; 2021 Jun; 38(6):1067-1079. PubMed ID: 34100216
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Banstola A; Duwa R; Emami F; Jeong JH; Yook S
Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
[TBL] [Abstract][Full Text] [Related]
6. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
7. Modulating Wnt/β-Catenin Signaling Pathway on U251 and T98G Glioblastoma Cell Lines Using a Combination of Paclitaxel and Temozolomide, A Molecular Docking Simulations and Gene Expression Study.
Jamalpour S; Alinezhad A; Sabah JT; Vazifehmand R; Behrooz AB; Hamzah ASA; Davazdahemami AA; Homaie FM; Maddah SM
Chem Pharm Bull (Tokyo); 2023; 71(10):766-774. PubMed ID: 37779078
[TBL] [Abstract][Full Text] [Related]
8. Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L; Tang S; Yu Y; Lv Y; Wang A; Yan X; Li N; Sha C; Sun K; Li Y
Mol Pharm; 2021 Mar; 18(3):915-927. PubMed ID: 33417456
[TBL] [Abstract][Full Text] [Related]
9. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
10. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
[TBL] [Abstract][Full Text] [Related]
11. LINC00511 facilitates Temozolomide resistance of glioblastoma cells via sponging miR-126-5p and activating Wnt/β-catenin signaling.
Lu Y; Tian M; Liu J; Wang K
J Biochem Mol Toxicol; 2021 Sep; 35(9):e22848. PubMed ID: 34328678
[TBL] [Abstract][Full Text] [Related]
12. Induction Therapy of Retinoic Acid with a Temozolomide-Loaded Gold Nanoparticle-Associated Ultrasound Effect on Glioblastoma Cancer Stem-Like Colonies.
Fadera S; Chen PY; Liu HL; Lee IC
ACS Appl Mater Interfaces; 2021 Jul; 13(28):32845-32855. PubMed ID: 34235925
[TBL] [Abstract][Full Text] [Related]
13. EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Yu T; Zhou F; Tian W; Xu R; Wang B; Zeng A; Zhou Z; Li M; Wang Y; Zhang J
Oncogene; 2023 Feb; 42(6):461-470. PubMed ID: 36517590
[TBL] [Abstract][Full Text] [Related]
14. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
15. Pam
Megías J; Martínez A; San-Miguel T; Gil-Benso R; Muñoz-Hidalgo L; Albert-Bellver D; Carratalá A; Gozalbo D; López-Ginés C; Gil ML; Cerdá-Nicolás M
Invest New Drugs; 2020 Apr; 38(2):299-310. PubMed ID: 31076963
[TBL] [Abstract][Full Text] [Related]
16. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Uram Ł; Markowicz J; Misiorek M; Filipowicz-Rachwał A; Wołowiec S; Wałajtys-Rode E
Eur J Pharm Sci; 2020 Sep; 152():105439. PubMed ID: 32615261
[TBL] [Abstract][Full Text] [Related]
18. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.
Lan F; Pan Q; Yu H; Yue X
J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372
[TBL] [Abstract][Full Text] [Related]
19. The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.
Xu Y; Shen M; Li Y; Sun Y; Teng Y; Wang Y; Duan Y
Oncotarget; 2016 Apr; 7(15):20890-901. PubMed ID: 26956046
[TBL] [Abstract][Full Text] [Related]
20. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]